Using the Coronary Artery Calcium Score to Guide Statin Therapy

Slides:

Advertisements

Similar presentations

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.

Advertisements

American College of Cardiology/American Heart Association Expert Consensus Document on Electron- Beam Computed Tomography for the Diagnosis and Prognosis.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.

Introduction Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence.

From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M

Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

2013 ACC/AHA cholesterol treatment guidelines

Markov model structure

From: Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical.

Volume 17, Issue 2, Pages (March 2014)

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

Gulf Survey of Atrial Fibrillation Events (Gulf SAFE)‏

Arterioscler Thromb Vasc Biol

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

Complexities of Genetic Testing in Familial Dilated Cardiomyopathy

Value-Based Hypothesis Testing for Cardiac Device Clinical Trials

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

Behavior and Biology: The Basic Sciences for AHA Action

Physician and Patient Influences on Provider Performance

Circ Cardiovasc Qual Outcomes

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Circ Cardiovasc Qual Outcomes

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Effect of Provider Volume on the Accuracy of Hospital Report Cards

New Frontiers in Cardiology

Iatrogenic Adverse Events in the Coronary Care Unit

by Johan Denollet, Angélique A. Schiffer, and Viola Spek

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Mathematical representation of Bayes theorem.

Circ Cardiovasc Qual Outcomes

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

Circ Cardiovasc Qual Outcomes

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Pulse Pressure and Resistance Artery Structure in the Elderly

Circ Cardiovasc Interv

Zhi-hui Hou et al. JIMG 2012;5:

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

Neil J. Stone et al. JACC 2014;63:

Volume 144, Issue 1, Pages e6 (January 2013)

Eric Peterson Journal of Indian College of Cardiology

Erythropoietic Growth Factors for Treatment-Induced Anemia in Hepatitis C: A Cost- Effectiveness Analysis Brennan M.R. Spiegel, Kristina Chen, Chiun–Fang.

Contemporary Evidence-Based Guidelines

Khurram Nasir et al. JACC 2015;66:

Decision analysis to define the optimal management of athletes with anomalous aortic origin of a coronary artery Carlos M. Mery, MD, MPH, Keila N. Lopez,

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer Thibaut Lizée, MD, Ethan Basch, MD, MSc, Pierre Trémolières,

Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.

Cost-effectiveness acceptability frontier for three risk-assessment strategies related to pressure-injury prevention best practices from a US societal.

Probabilistic sensitivity analysis.

Cost-effectiveness acceptability curves (CEAC) of tight control versus clinical management excluding (base case) and including absenteeism due to Crohn’s.

Lars Oddershede, MMS, Jan J. Andreasen, MD, PhD, Barbara C

Presentation transcript:

Using the Coronary Artery Calcium Score to Guide Statin Therapy by Mark J. Pletcher, Michael Pignone, Stephanie Earnshaw, Cheryl McDade, Kathryn A. Phillips, Reto Auer, Lydia Zablotska, and Philip Greenland Circ Cardiovasc Qual Outcomes Volume 7(2):276-284 March 18, 2014 Copyright © American Heart Association, Inc. All rights reserved.

Probability of cost-effectiveness of treat all, treat none, and coronary artery calcium (CAC) screening strategies at different willingness-to-pay thresholds. Probability of cost-effectiveness of treat all, treat none, and coronary artery calcium (CAC) screening strategies at different willingness-to-pay thresholds. These acceptability curves illustrate probabilistic results from 10 000 model runs of the base-case clinical scenario (a 55-year-old woman with high cholesterol), under both favorable and unfavorable statin assumption scenarios, that account for the uncertainty in parameter estimates described in Table I in the Data Supplement. The decision to measure CAC is sensitive to the willingness-to-pay threshold when unfavorable assumptions about statins are used. A disutility of 0.00384 is equivalent to 2 weeks of perfect health traded away to avoid 10 years on statins. QALY indicates quality-adjusted life-years. Mark J. Pletcher et al. Circ Cardiovasc Qual Outcomes. 2014;7:276-284 Copyright © American Heart Association, Inc. All rights reserved.